Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint
KPTI•Safety was consistent; company to shift focus
Detailed findings have not been presented yet; management expects to disclose the full dataset at a future medical meeting.
Safety was consistent with prior experience, with no new issues flagged.
Karyopharm plans to scale back endometrial cancer investment, shifting focus to myelofibrosis and multiple myeloma programs.
Phase 3 maintenance trial misses primary endpoint
Karyopharm reported topline results from its Phase 3 XPORT-EC-042 maintenance trial of selinexor in advanced or recurrent endometrial cancer.
The study missed its main goal, though results showed a directional benefit for selinexor versus placebo.
